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Introduction
Forming a mechanical boundary against pathogens, antigens, 
and toxins, the monolayer of intestinal epithelial cells (IECs) 
represents the human body’s largest contact area with the envi-
ronment (1). From their early development in the crypt bottom 
until shedding of aged cells at the villus tip, IECs follow a con-
tinuous turnover process (2–4). Under physiological conditions, 
a complex interaction between cytoskeleton rearrangement and 
tight junction proteins guarantees that the cell shedding itself 
does not mean a disturbance of epithelial integrity (5). However, 
alterations of epithelial integrity may lead to development of gut 
inflammatory disorders (1, 6), such as inflammatory bowel dis-
eases (IBDs) (7). IBDs are associated with marked alterations of 
IECs, leading to increased tight junction permeability, altered 
cytoskeletal rearrangement, and induction of epithelial cell death 
with a subsequent loss of barrier function (1, 6). In vivo studies 
in IBD patients demonstrated that loss of IEC integrity even pre-
ceded the clinical relapse of disease (8), suggesting that alteration 
of barrier function is crucial in the pathogenesis of IBDs. How-
ever, the exact IEC intrinsic mechanisms involved in the initia-
tion of barrier dysfunction remain enigmatic.
On a subcellular level, Rho GTPases represent signaling 
molecules centrally involved in arrangement of cytoskeletal pro-
teins and epithelial cell dynamics (9–13). Since their activation 
preferentially takes place when GTPases are associated with 
cellular membranes (14, 15), function of Rho proteins crucially 
depends on their intracellular localization (16). Recruitment of 
small GTPases is governed by prenylation, a posttranslational 
process consisting of the attachment of hydrophobic isopre-
noids to the C-terminal CAAX motif of the protein (17). In the 
intestinal epithelium, it has been shown that apoptotic as well 
as physiological cell extrusion requires Rho-mediated signaling 
pathways (18, 19). Moreover, Rho-A/ROCK/Myosin II interac-
tion is known to be important for morphogenesis of the prim-
itive gut tube in Xenopus (20). However, little is known about 
regulation of Rho-A signaling in the intestinal epithelium and 
its impact on gut homeostasis in vivo.
Using gene expression profiling of IECs from inflamed versus 
uninflamed tissue, we identified altered Rho-A signaling in IBD 
patients. Although Rho-A was expressed at normal levels, cyto-
solic accumulation of Rho-A in IECs suggested impaired Rho-A 
activation via prenylation upon inflammation. Consistently, 
genetic deletion of Rhoa or Pggt1b (encoding for the prenylation-
catalyzing enzyme geranylgeranyltransferase-I [GGTase-I] driv-
ing Rho-A activation) in murine IECs impacted on cytoskeleton 
and cell shedding, resulting in epithelial injury and spontaneous 
gut inflammation. Our data demonstrate that injury in GGTase-I–
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information of included patients is summarized in Supplemental 
Table 1 (supplemental material available online with this article; 
doi:10.1172/JCI80997DS1). Comparative genomic expression 
analysis of IECs from inflamed versus uninflamed gut areas of CD 
patients showed that samples within each group clustered, and we 
were able to identify 129 genes differing significantly (fold-change 
≥ 1.5; P ≤ 0.05) between both groups (Figure 1A). Interestingly, 
gene ontology analyses indicated inflammation-associated down-
regulation of pathways involved in epithelial cell dynamics and IEC 
extrusion, such as Rho-A signaling, epithelial adherens junctions, 
and regulation of actin-based motility by Rho (Figure 1B). Notably, 
pathways involving Rho GTPases other than Rho-A, such as Cdc42 
signaling, showed no significant changes (Supplemental Figure 
1A). Although our data implicated a relation between impaired 
Rho-A function in IECs and inflammation in human IBDs, nei-
ther protein nor mRNA expression levels of Rho-A were found to 
be reduced in IECs from inflamed gut areas of CD or ulcerative 
deficient epithelium was driven by Rho-A dysfunction and that 
this phenotype could be successfully reversed by Rho activation. 
Together, our study highlights for the first time to our knowledge 
the relevance of functional Rho-A signaling and its regulation via 
prenylation for maintenance of epithelial integrity. Thus, preny-
lated Rho-A in epithelium emerges as a therapeutic target in IBDs.
Results
A crucial role of epithelial Rho-A in intestinal inflammation. Intesti-
nal erosions and ulcers caused by epithelial injury represent clini-
cal hallmarks of IBDs, but the underlying pathogenesis of epithelial 
disruption in the context of gut inflammation is not fully under-
stood. To identify alterations in signaling pathways in intestinal 
epithelium upon inflammation, we used a heuristic approach and 
performed gene expression arrays in purified IECs from Crohn’s 
disease patients (CD patients) (array data accessible through 
NCBI’s Gene Expression Omnibus [GEO GSE72780]). Clinical 
Figure 1. Gene expression array comparing IECs isolated from uninflamed and inflamed gut areas of CD patients. (A) Heat map showing differentially 
expressed genes in IECs (fold-change ≥ 1.5; P ≤ 0.05). (B) Top 20 regulated canonical pathways. Data are expressed as –log (P value). P value was obtained 
by independent sample t test (Ingenuity analysis). n = 9.
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ular, the small intestine of Rho-AΔIEC mice could be characterized 
by crypt abnormalities, villous blunting, reduced number of gob-
let cells (Figure 3, C and D, and Supplemental Figure 2A), marked 
infiltration of CD4+ T cells and neutrophils (Figure 3E and Supple-
mental Figure 2B), and significantly elevated levels of Tnfa (Figure 
3F) compared with Rhoafl/fl littermates. Colon tissue turned out to 
be less affected, and the increased numbers of CD4+ T cells and 
increased mucosal TNF-α levels in the colon of Rho-AΔIEC mice did 
not reach statistical significance as compared with WT animals 
(Supplemental Figure 2, C and D). Interestingly, the observed intes-
tinal phenotype of Rho-AΔIEC mice was not derived from a devel-
opmental problem during embryogenesis, since neonates from 
Rho-AΔIEC mice appeared to be healthy, showed no reduced body 
weight, and did not differ from Rhoafl/fl littermates with regard to 
intestinal tissue structure (Supplemental Figure 2, E–G). Our data 
therefore identified epithelial Rho-A as a key regulator in the main-
tenance of intestinal homeostasis and epithelial cell architecture. 
The altered epithelial structure in Rho-AΔIEC mice was associated 
with a significantly increased intestinal permeability (Figure 3G), 
suggesting that epithelial Rho-A deficiency leads to impairment of 
intestinal barrier function.
colitis patients (UC patients) compared with uninflamed tissue 
(Figure 2A and Supplemental Table 2). However, while — in IECs 
of control patients — Rho-A was detected almost exclusively at the 
plasma membrane, IECs in inflamed areas of gut were character-
ized by a prominent cytosolic accumulation of Rho-A (Figure 2B, 
Supplemental Figure 1, B and C, and Supplemental Table 3), sug-
gesting a predominance of inactive Rho-A in IECs of IBD patients. 
Similarly, cytosolic Rho-A enrichment upon inflammation could 
also be confirmed in IECs from dextran sulfate sodium–exposed 
(DSS-exposed) mice (Figure 2C and Supplemental Figure 1D), 
suggesting a link between dysfunction of epithelial Rho-A and gut 
inflammation. To further address the functional consequences of 
impaired epithelial Rho-A, we generated mice with an IEC-specific 
deletion of Rhoa (Rho-AΔIEC mice) by crossbreeding mice carrying 
the LoxP-flanked Rhoa gene (21) with mice expressing Cre-recom-
binase under the control of the epithelium-specific villin promoter 
(22). Lack of Rho-A in IECs resulted in decreased body weight 
(Figure 3A) and spontaneous mucosal inflammation in the small 
intestine, as indicated by high resolution colonoscopy (Figure 3B). 
Evaluation of inflammatory tissue alteration by histologic scoring 
confirmed small intestinal pathology in Rho-AΔIEC mice. In partic-
Figure 2. Rho-A profile in human and murine colitis. (A) Rho-A protein expression in IECs isolated from human gut; blots are representative of 2 experi-
ments (top); and Rhoa mRNA expression (bottom) in IECs isolated from human gut. Mean values ± SEM are shown (controls, n = 4; IBD uninflamed, n = 9;  
CD, n = 5; UC, n = 4). No statistical significance, 1-way ANOVA with LSD multiple comparisons test. (B) Representative pictures and quantification from 
Rho-A immunostaining (red) in human gut samples. Sections were counterstained with EpCAM (green) and Hoechst (blue). Arrows indicate cytosolic accu-
mulation of Rho-A. Bars show percentage of cells with cytosolic Rho-A (2 villi or crypts/sample; 30 IEC/sample). Mean values ± SEM (controls, n = 5; IBD 
uninflamed, n = 7; CD, n = 3; UC, n = 3). ††P ≤ 0.001 vs. control; *P ≤ 0.05 vs. IBD-uninflamed; 1-way ANOVA with LSD multiple comparisons test. Original 
magnification, ×63, zoom ×4. (C) Western blot analysis of Rho-A in cytosolic and total proteins from colonic IECs from DSS-exposed and unchallenged 
mice. Blots are representative of 2 experiments (n = 4/group). Con, control; un, uninflamed; infl, inflamed.
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in mice. In this model, significantly decreased GGTase-I expres-
sion went along with accumulation of nonprenylated (Np) proteins 
in IECs upon inflammation, indicated by an increased detection of 
Np small GTPase Rap1A (Np-Rap1A) (Figure 4, C and D, and Sup-
plemental Figure 3, B and C). Thus, deficient prenylation in IECs 
upon inflammation might be responsible for altered subcellular 
localization and signaling of Rho-A in IBDs.
To gain further insights into the signaling mechanisms control-
ling Pggt1b expression in gut epithelium, epithelial organoids were 
cultured in the presence of different proinflammatory cytokines. 
Use of gut organoid technique allowed us to perform our analyses 
in the absence of extraepithelial factors (24). Interestingly, expo-
sure to the IBD hallmark cytokine IL-6 (25) resulted in a signifi-
Deficient prenylation in the inflamed intestinal epithelium of CD 
and UC patients. Since impaired Rho-A signaling in IBDs could not 
be explained by decreased Rho-A expression (Figure 2A), we pos-
tulated an impaired activation of epithelial Rho-A under inflam-
matory conditions via prenylation, a posttranslational modifica-
tion necessary for membrane affinity of this GTPase (23). Notably, 
expression analysis of the Rho-A–associated prenylation-catalyz-
ing enzyme GGTase-I indicated significantly diminished protein 
and mRNA levels in IECs of CD and UC patients during mucosal 
inflammation (Figure 4, A and B, Supplemental Figure 3A, and 
Supplemental Tables 3 and 4). The association between intestinal 
inflammation and diminished GGTase-I expression could be fur-
ther confirmed in the experimental model of DSS-induced colitis 
Figure 3. Phenotype of Rho-AΔIEC mice. (A) Body weight of control and Rho-AΔIEC mice; percentage is calculated over the mean body weight of control mice 
on week 4. (n = 9). (B) Representative miniendoscopy pictures of different gut segments (3 experiments). (C) Representative H&E pictures (3 experi-
ments). Original magnification, ×20. (D) Histological score quantification of different gut segments (n = 9). (E) Quantification of cell infiltration in ileum 
(immunofluorescence staining). n = 6/group. (F) Tnfa expression in ileum measured by qPCR. (n = 6/group). (G) Serum concentration of orally administered 
FITC-Dextran. n = 4/group. Data represent mean ± SEM in A and D–G. †P ≤ 0.05 and ††P ≤ 0.001 vs. control, independent samples t test, in A, D, F, and G.
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differenced in Rhoa expression could not be observed when we 
analyzed total gut tissue (Supplemental Figure 4B), our data fur-
thermore suggest that regulation of intestinal Rhoa expression 
specifically occurs within the epithelial compartment.
Deficient prenylation within IECs results in alteration of cell 
shedding and loss of gut homeostasis. To further characterize the 
impact of prenylation on Rho-A signaling and intestinal inflam-
mation in vivo, we created a mouse line with inducible conditional 
Pggt1b deficiency in IECs. Breeding of Pggt1bfl/fl mice (26) with 
villin-Cre-ERT2 mice (22) (tamoxifen induces ERT2-dependent 
Cre-recombinase expression) led to the generation of Pggt-IβTiΔIEC 
mice, which developed normally and showed no signs of intes-
tinal pathology before tamoxifen treatment (data not shown). 
Tamoxifen-induced specific deletion of Pggt1b within IECs caused 
cantly decreased Pggt1b expression in epithelial organoids (Figure 
5A), suggesting that pathologically increased IL-6 signaling in 
the inflamed gut of IBD patients contributes to downregulation 
of Pggt1b expression and subsequent impairment of Rho-A activ-
ity in IECs. By comparing IECs in colon and small intestine, we 
observed contrary expression patterns for Il6 and Pggt1b with high 
Il6 (Supplemental Figure 4A) and relatively low Pggt1b expression 
(Figure 5B) in the small intestine. Our data therefore implicate that 
regional as well as inflammation-induced alteration of prenylation 
levels in IECs might be augmented by IL-6. Besides relatively low 
levels of Pggt1b expression, IECs in small intestine could also be 
characterized by a decreased expression of Rhoa mRNA compared 
with IECs in colon (Figure 5B), making the small intestine poten-
tially more susceptible to Rhoa and Pggt1b inhibition. As regional 
Figure 4. GGTase-Iβ profile in human and murine colitis. (A) GGTase-Iβ protein expression in IECs isolated from human gut; blots are representative of 2 
experiments. The same samples are shown in Figure 2A (top); Pggt1b mRNA expression (bottom) in IECs isolated from human gut. (control, n = 3; IBD unin-
flamed, n = 7; CD, n = 3; UC, n = 4). †P ≤ 0.05 vs. control; *P ≤ 0.05 vs. IBD uninflamed. (B) Representative pictures and quantification of GGTase-Iβ immu-
nostaining (red) in human gut samples. (control, n = 6; IBD uninflamed, n = 7; CD, n = 7; UC, n = 5). Bars show percentage of cells expressing GGTase-Iβ (2 villi 
or crypts/sample; 60 IECs/sample). ††P ≤ 0.001 vs. control; *P ≤ 0.05 vs. IBD uninflamed. Original magnification, ×63. (C) GGTase-Iβ expression in IECs from 
DSS-exposed mice: mRNA expression, measured by qPCR (n = 8/group). †††P ≤ 0.0001 vs. control (top); representative blot out of 3 experiments (bottom). 
(D) GGTase-Iβ immunostaining (red) in colon from DSS-treated mice. Mean intensity quantification (n = 8/group). Original magnification, ×63. †P ≤ 0.05 vs. 
control. Immunostainings were counterstained with EpCAM (green) and Hoechst (blue) in B and D. Mean values ± SEM are shown in A–D. One-way ANOVA 
with LSD multiple comparisons test were used in A and B. Independent samples t test was used in C and D. Con, control; un, uninflamed; infl, inflamed.
Downloaded from http://www.jci.org on February 18, 2016.   http://dx.doi.org/10.1172/JCI80997
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
6 1 6 jci.org   Volume 126   Number 2   February 2016
a decrease of epithelial Pggt1b mRNA (Supplemental Figure 5, A 
and B) and GGTase-I protein expression and, subsequently, an 
enrichment of Np proteins (Figure 6, A and B, and Supplemental 
Figure 5C). Such deletion resulted in body weight loss (Figure 7A), 
while Pggt1bfl/fl control mice remained unaffected. Macroscopic, 
endoscopic, and histological analyses identified chronic intestinal 
inflammation and injury in Pggt-IβTiΔIEC mice (Figure 7, B–E). The 
colon showed signs of moderate inflammation that did not reach 
statistical significance, whereas significant marked destruction of 
the villus-crypt architecture and loss of epithelial integrity could 
be observed in the small intestine of Pggt-IβTiΔIEC mice as com-
pared with floxed control mice (Figure 7E). Immunofluorescence 
and biochemistry analyses of small intestine tissue demonstrated 
that inflammatory injury of small intestine in Pggt-IβTiΔIEC mice 
went along with a massive infiltration of CD4+ T cells, macro-
phages, and neutrophils (Figure 7F) and significantly increased 
levels of proinflammatory cytokines, such as IL-1β, IL-6, and 
TNF-α (Figure 7G and Supplemental Figure 5D). Colon tissue of 
Pggt-IβTiΔIEC mice showed only moderate alterations with regard 
to inflammatory cell infiltration and cytokine production (Supple-
mental Figure 5, E an F). To investigate whether deficient prenyla-
tion in IECs might compromise the gut barrier, we next subjected 
mice to FITC-dextran oral gavage. We noted a significantly higher 
increase of FITC serum levels in Pggt-IβTiΔIEC mice as compared 
with control mice, suggesting a breakdown of intestinal barrier 
function (Figure 7H). Time course studies furthermore indicated 
that development of epithelial injury and impairment of gut bar-
rier after Pggt1b deletion even preceded induction of proinflam-
matory cytokine production (Supplemental Figure 6). The loss of 
intestinal barrier function therefore appeared as a primary defect 
in Pggt-IβTiΔIEC mice.
To investigate whether prenylation might be an essential pro-
cess for epithelial cell survival, we next studied epithelial devel-
opment in organoids (24) from Pggt-IβTiΔIEC mice. Pggt1b deletion 
impaired the maintenance of complex epithelial organization and 
resulted in destruction and death of ex vivo cultured and tamox-
ifen-exposed organoids from Pggt-IβTiΔIEC mice (Figure 8 and 
Supplemental Figure 7), suggesting that GGTase-I activity acts as 
an epithelial-intrinsic factor controlling cell survival. These data 
clearly demonstrated that gut epithelial organization and integrity 
directly depend on prenylation within IECs.
Dysregulation of apoptosis and necroptosis in IECs has been 
previously described to cause intestinal inflammation via loss of 
barrier function (4). To investigate whether excessive epithelial 
cell death might be a key driving factor of the severe phenotype 
occurring in Pggt-IβTiΔIEC mice, we determined whether apoptosis 
or necroptosis might play an important role. However, neither the 
additional IEC-specific deletion of Casp8, nor that of the necrop-
Figure 5. Regulation of GGTase-Iβ and Rho-A expression in intestinal epithelium. (A) Pggt1b and Rhoa mRNA expression (measured by qPCR) in 
cytokine-treated intestinal organoids from unchallenged WT mice (20 ng/ml of the cytokine, 8 hours stimulation) (n = 3/group). †P ≤ 0.05 vs. control; 
independent samples t test. (B) Pggt1b and Rhoa mRNA expression in IECs isolated from different gut segments from unchallenged WT mice (n = 4/
group). †P ≤ 0.05; 1-way ANOVA with LSD multiple comparisons test. Bars show mean ± SEM in A and B.
Figure 6. Validation of tamoxifen-induced Pggt1b deletion in IECs 
(Pggt-IβTiΔIEC mice). Pggt-IβTiΔIEC mice were treated for 3 consecutive days 
with tamoxifen by i.p. injection. Day 0 was defined as the day of the first 
tamoxifen injection. (A) Western blot of GGTase-Iβ and Np-Rap1A in 
isolated IECs; blots are representative of 3 independent experiments. (B) 
Representative pictures of GGTase-Iβ (red) and Np-Rap1A (red) immuno-
stainings in duodenum (n = 4/group). Sections were counterstained with 
EpCAM (green) and Hoechst (blue). Original magnification, ×63.
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tosis inducer Rip3k, rescued the lethal consequence of Pggt1b dele-
tion (Supplemental Figure 8, A–D). Additionally, proliferation of 
IECs along the crypt axis was not reduced in the absence of epithe-
lial GGTase-I (Supplemental Figure 8E), excluding the possibility 
that cell proliferation arrest is a key underlying mechanism for tis-
sue injury in Pggt-IβTiΔIEC mice.
Our finding of severe barrier dysfunction in the absence of 
alterations in key homeostatic mechanisms finally led us to study 
epithelial cell shedding, a process crucial for the regulation of epi-
thelial turnover in the steady state. Notably, using in vivo confocal 
microscopy of the gut (5), we observed marked alterations of the 
monolayer due to the occurrence of epithelial gaps in Pggt-IβTiΔIEC 
mice but not control mice (Figure 9A). Under physiological condi-
tions, such gaps are formed by the shedding of epithelial cells and 
sealed by neighboring cells (3, 5, 27) to avoid breakdown of barrier 
function. To determine whether barrier function and cell shed-
ding were altered in Pggt-IβTiΔIEC mice, as recently observed in 
IBD patients (8, 28, 29), we performed in vivo rhodamine leakage 
assays. These studies revealed an increased passage of topically 
applied dextran from the lumen to the lamina propria in Pggt-IβTiΔIEC 
Figure 7. Phenotype of Pggt-IβTiΔIEC mice. (A) Body weight of control and Pggt-IβTiΔIEC mice (percentage of mean body weight on day 0). n = 6/group; †P ≤ 0.05 
and ††P ≤ 0.001 vs. control. (B) Macroscopic pictures of whole gut (3 experiments). (C) Mini-endoscopic pictures (3 experiments). (D) H&E pictures. Original 
magnification, ×10; insets, ×40. (E) Histological score quantification of different gut segments (n = 6/group). †P ≤ 0.05 and †††P ≤ 0.0001 vs. control. (F) 
Quantification of cell infiltration in duodenum (immunofluorescence staining). n = 6/group. (G) TNF-α expression in duodenum measured by qPCR. n = 2/
group; representative of 3 experiments. (H) Serum concentration of orally administered FITC-Dextran (n = 4). Mean ± SEM in A and E–H. †P ≤ 0.05 vs. control 
in F–H. Independent samples t test, in A and E–H. Duoden, duodenum.
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Electron microscopic analysis of GGTase-I–deficient IECs 
revealed disruption of the epithelial architecture and altered 
cytoskeleton rearrangement (Figure 10A). Consistently, local-
ization of actin fibers and myosin IIA within IECs was no longer 
restricted to the apical cell membrane in the absence of GGTase-I, 
but it spread along lateral membranes and also in the cytosol (Fig-
ure 10B and Supplemental Figure 10A). Cytoskeleton rearrange-
ment was analyzed by kinome array of GGTase-I–deficient IECs. 
as compared with control mice (Figure 9B and Supplemental 
Figure 9A). Villus tips in Pggt-IβTiΔIEC mice showed marked accu-
mulation of leakage points and appearance of dextran-perme-
able IECs (Figure 9C), suggesting altered epithelial cell integ-
rity. Furthermore, cell shedding was increased in Pggt-IβTiΔIEC 
mice (Supplemental Figure 9B), consistent with the barrier loss 
and suggesting shedding alterations as key processes mediating 
the phenotype of Pggt-IβTiΔIEC mice.
Figure 8. Development and survival of GGTase-Iβ–deficient organoids. Small intestinal crypts isolated from control and Pggt-IβTiΔIEC mice were treated 
with tamoxifen in vitro. (A) Representative microscopic pictures out of 3 independent experiments. Original magnification, ×10. (B and C) Cell death stain-
ing measured by propidium iodide incorporation (red) as described in Methods. Nuclei were counsterstained with Hoechst (blue). Representative pictures; 
original magnification, ×20 (n = 17) (B). Quantification of normalized mean fluorescence intensity (red/blue). Bars show mean values ± SEM (n = 17) (C).  
†P ≤ 0.05 vs. control; independent sample t test.
Figure 9. Epithelial turnover and integrity within GGTase-Iβ–deficient epithelium. (A) Representative in vivo images of small intestinal villi stained 
with acriflavine (green) (3 independent experiments). Arrows indicate epithelial gaps. Original magnification, ×40. (B) Live imaging of cell shedding in the 
small intestine from control and Pggt-IβTiΔIEC mice; acriflavine (green), and luminal rhodamine-dextran (red). Representative pictures out of 2 experiments. 
Original magnification, ×20. (C) Representative pictures and quantification of leakage entry points (red arrow) and permeable IECs (white arrow). Original 
magnification, ×40. Mean ± SEM; n = 8/group. †P ≤ 0.05 and †††P ≤ 0.0001 vs. control mice; independent samples t test.
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genes were regulated in IECs of Pggt-IβTiΔIEC mice as compared 
with control mice (fold-change ≥ 2; P ≤ 0.05) (Figure 11, A and B). 
Gene ontology analysis from GGTase-I–deficient IECs implicated 
an association between GGTase-I prenylation and cell viability/
cell death induction, cytoskeleton rearrangement, and cell mor-
phology (Figure 11, C and D, and Supplemental Table 5), consis-
tent with our mechanistic observations and previous findings on 
potential Rho targets (30). Interestingly, when we compared the 
gene expression profile in IECs from IBD patients and GGTase-I–
deficient IECs, Rho-A signaling could be identified as one of the 
only 2 pathways significantly regulated in both conditions (Figure 
11E). Beside Rho-A signaling, only the aryl hydrocarbon receptor 
(AHR) pathway (31) was regulated in both settings, but it seemed 
to be of minor functional relevance, since the expression of AHR 
repressor (AHRR) (32) turned out to be unchanged in IECs from 
Pggt-IβTiΔIEC mice (Supplemental Figure 11). Furthermore, Rho-A– 
and GGTase-I–deficient IECs resembled each other in the accu-
mulation of arrested cell shedding events (Figure 10, B and C, and 
Figure 12, A and B) and in their inability to form regular organoid 
structures (Figure 12C). Together, these data strongly suggested 
that impairment of Rho-A signaling represents the pivotal conse-
quence of deficient GGTase-I activity in IECs, relevant for epithe-
lial integrity and IBD pathogenesis.
Phosphorylation of 19 out of 64 cytoskeleton-related proteins was 
modified, and many of these proteins are known to be involved in 
Rho-A regulation (Supplemental Figure 10B). Since cytoskeleton 
rearrangement and tight junction redistribution represent one of 
the early events occurring in cell shedding (27), we hypothesized 
that cell shedding was arrested in Pggt-IβTiΔIEC mice. Hence, we 
quantified the number of IECs showing redistribution of actin 
fibers (funnel-like structures, arrested events) versus cells that 
have been already shed into the lumen (nucleus does not belong 
to the monolayer, completed events) (Supplemental Figure 10C). 
Indeed, the accumulation of arrested (early) versus completed 
(late) shedding events in GGTase-Iβ–deficient small intestine 
(Figure 10C) indicated an impaired completion of cell extrusion. 
Accumulated half-shed cells might subsequently impair the nor-
mal cytoskeletal mechanisms to seal the resulting gap.
Mucosal inflammation in the absence of GGTase-I is driven by 
blockade of Rho-A signaling. In order to further analyze the inter-
play between deficient prenylation, impaired Rho-A signaling, 
and epithelial injury, we next performed a more profound char-
acterization of molecular alterations in GGTase-Iβ–deficient 
IECs. Quantitative proteomic and gene expression assays (array 
data accessible through NCBI’s GEO [GSE72781]) revealed that 
the steady-state levels of 322 proteins and the expression of 725 
Figure 10. Cytoskeleton rearrangement and cell shedding within GGTase-Iβ–deficient epithelium. (A) Representative electron microscopic pictures from 
duodenum of Pggt-IβTiΔIEC and control mice. Arrows indicate invaginations (red), apical network fibers (blue), and filamentous ultrastructure (yellow) (2 
independent experiments). Original magnification, ×5,000; insets ×20,000. (B) Representative pictures from phalloidin staining of F-actin fibers (green) in 
colon and duodenum from Pggt-IβTiΔIEC mice (3 independent experiments). Nuclei were counterstained with Hoechst. Arrows indicate redistribution of actin 
fibers. Original magnification, ×63. (C) Quantification of arrested vs. completed shedding events, expressed as percentage of total shedding events. Mean 
values ± SEM; n = 11 (colon); n = 7 (duodenum).
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furthermore pointed to a potential therapeutic applicability of 
Rho activators for treatment of epithelial-derived gut pathology.
Discussion
Epithelial injury represents an important but not fully understood 
aspect of IBD pathogenesis (33). While recent studies have shown 
that epithelial injury in IBDs can be initiated by mechanisms reg-
ulating cell death in IECs, such as apoptosis and necroptosis (34), 
we here identified a new mechanism of epithelial damage in IBDs 
induced by impaired Rho-A signaling with subsequent cytoskele-
tal alterations of IECs and altered cell shedding. Such abnormal 
cell shedding may cause intestinal erosions and ulcer formation 
in IBDs and favors impaired barrier function that may clinically 
precede the development of acute flares in IBD patients (8, 27–29).
In the inflamed gut, epithelial-extrinsic mediators, such as 
proinflammatory cytokines derived from activated lamina pro-
pria immune cells (TNF-α, IL-6, and IL-13) (35–37), are potent 
inducers of IEC apoptosis and pathological cell shedding with 
subsequent impairment of epithelial barrier function (35, 37–
40). However, an increased occurrence of abnormal intestinal 
permeability in healthy relatives from IBD patients (41), and 
the finding that loss of barrier function in IBDs often preceded 
the clinical relapse of disease (8, 28), strongly argue against the 
assumption that IBD-associated epithelial barrier defects rep-
In line with this suggestion, GGTase-Iβ–deficient IECs 
showed a substantial decrease of membrane-bound and an accu-
mulation of cytosolic Rho-A (Figure 13, A and B, and Supplemen-
tal Figure 12A), while other small Rho GTPases did not show this 
profile (Supplemental Figure 12B). Reduced membrane-localiza-
tion of Rho-A in IECs of Pggt-IβTiΔIEC mice was paralleled by inef-
ficient GTPase activation, resulting in reduced levels of active 
GTP-bound Rho-A (Figure 13C), and decreased phosphorylation 
of the downstream Rho-A target protein myosin light-chain 2 
(MLC2) (Figure 13D). Thus, we confirmed that Rho-A activa-
tion and signaling is markedly impaired in IECs in the absence 
of GGTase-I. On a functional level, we wondered whether acti-
vation of Rho-A signaling would rescue the intestinal pathology 
in Pggt-IβTiΔIEC mice and, thus, treated these mice with Rho acti-
vators. Analysis of Pggt-IβTiΔIEC mice exposed to the specific Rho 
activator CN03 indicated that successful triggering of Rho-A 
activity in IECs in vivo (Supplemental Figure 12C) resulted in a 
significant amelioration of mucosal damage in endoscopy (Fig-
ure 14, A and B), a clear tendency toward decreased histological 
damage score (P = 0.054) (Figure 14, C and D), and significantly 
diminished expression of Il1b and Il16 in the duodenum (Fig-
ure 14E) as compared with untreated mice. Rho-A blockade via 
impaired prenylation thus emerged as a key driver of mucosal 
damage in Pggt-IβTiΔIEC mice. The observed in vivo effect of CN03 
Figure 11. Molecular consequence of diminished protein prenylation in IECs. (A) Heat map of genes significantly regulated in IECs from Pggt-IβTiΔIEC 
vs. control mice (n = 3 per group; fold-change ≥ 10; P ≤ 0.05; independent samples t test). (B) Heat map of proteins significantly regulated in IECs 
from Pggt-IβTiΔIEC vs. control mice (n = 3 for control and n = 2 for Pggt-IβTiΔIEC mice; fold-change ≥ 5; P ≤ 0.05; independent samples t test). (C and D) GO 
analysis. Representation of selected genes (C) and proteins (D) from Top 10 list clustered in groups related to their cellular function (fold-change). (E) 
Pathway analysis comparison between gene expression profiles in IECs from CD patients and Pggt-IβTiΔIEC mice (P ≤ 0.05). Independent sample t test.
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noted in the large intestine. This could be due to the compensatory 
effects of other small GTPases in the large intestine. The identifi-
cation of these GTPases will require further studies in the future.
Our findings indicate that epithelial integrity, intestinal archi-
tecture, and homeostasis critically depend on sufficient prenylation 
of Rho proteins within IECs. IEC-specific deletion of the enzyme 
GGTase-I resulted in intestinal disease characterized by accumu-
lation of inactive cytosolic Rho-A, epithelial injury, and mucosal 
inflammation. Likewise, abrogation of Rho-A in IECs led to marked 
epithelial alterations and intestinal inflammation. Our findings sug-
gested that impairment of GGTase-I–mediated prenylation in IECs 
causes accumulation of Np cytosolic Rho-A molecules that are func-
tionally inactive. This subsequently results in impaired regulation of 
cytoskeleton rearrangement (42) with instability of cell shape and 
alteration of cell shedding. Accumulation of arrested cell shedding 
events within the epithelial monolayer finally resulted in loss of bar-
rier function and pathologically increased intestinal permeability. 
Altered intestinal permeability may subsequently cause chronic 
intestinal inflammation. Indeed, time-course studies in inducible 
GGTase-I–deficient mice revealed that altered barrier function pre-
cedes mucosal inflammation, suggesting a primary barrier defect in 
such animals. The potential relevance of these findings for humans 
was underlined by the observation that significant downregulation 
of GGTase-I levels and cytosolic Rho-A accumulation was seen 
in the gut epithelium of IBD patients with active disease. Thus, in 
addition to the role of Rho-A signaling in cytoskeleton regulation 
(43), maintenance of cell shape (44), and cell migration (45), Rho-A 
emerges as a crucial regulator of gut epithelial homeostasis, and 
this function critically depends on cellular availability of prenylated 
Rho-A. Our findings indicated that Rho-A signaling is involved in 
epithelial cell shedding during inflammation. Consistently, inhibi-
resent a pure secondary phenomenon of chronic colitis. Instead, 
epithelial-intrinsic alterations may play a primary role in IBD 
pathogenesis, and their modulation might open a field for poten-
tial therapeutic or preventive interventions. In this context, the 
here described requirement for sufficient Rho-A prenylation in 
gut epithelium represents an interesting new aspect, which sig-
nificantly improves our understanding of intracellular regulation 
in IECs. In particular, the observation that Pggt1b deletion in ex 
vivo organoids impaired the maintenance of complex epithelial 
organization, even in the absence of any immune cell–derived 
factor, strongly supported the independency of Rho-A signaling 
cascades from epithelial-extrinsic mediators. On the other hand, 
the observed regulatory impact of IL-6 on GGTase-Iβ expres-
sion clearly demonstrated the high complexity of the interplay 
between epithelial and epithelial-extrinsic mediators in patho-
genesis of IBDs. Our observation that IECs in small intestine of 
unchallenged WT mice showed as significantly decreased expres-
sion of Rhoa mRNA compared with IECs in colon might implicate 
augmented susceptibility of the small intestine to Rho-A and 
GGTase-Iβ inhibition. It will therefore be important to investigate 
in future studies whether levels of epithelial Rho-A expression or 
activation along the gastrointestinal tract might indeed impact on 
regional differences in disease manifestations in IBD patients.
The functional relevance of Rho-A and GGTase-I–mediated 
Rho-A activation for functional integrity of the intestine was high-
lighted by studies in mice with conditional gene targeting in which 
deletion of Rhoa or Pggt1b in IECs caused spontaneous chronic 
intestinal inflammation with accumulation of granulocytes and 
CD4+ T cells and augmented production of the proinflammatory 
cytokine TNF-α. The phenotype of these mice was particularly 
prominent in the small intestine, while little inflammation was 
Figure 12. Epithelial integrity and turnover within Rho-A–deficient epithelium. (A) Cytoskeleton rearrangement within Rho-A–deficient IECs. Represen-
tative pictures from phalloidin staining of F-actin fibers (green) (3 experiments). Nuclei were counterstained with Hoechst. Arrows indicate redistribution 
of actin fibers. Original magnification, ×63, zoom ×3. (B) Quantification of arrested vs. completed shedding events in colon and duodenum, expressed as 
percentage of total shedding events. Mean values ± SEM; n = 3 per group. (C) Development of organoids generated from small intestinal crypts isolated 
from control and Rho-AΔIEC mice; representative pictures out of 2 experiments.
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O. Bergö (Sahlgrenska Cancer Center, Institute of Medicine, University 
of Gothenburg, Gothenburg, Sweden). Rhoafl/fl mice were provided by 
Cord Brakebusch (Biotech Research and Innovation Centre, University 
of Copenhagen, Copenhagen, Denmark). To generate specific deletion 
of Pggt1b or Rhoa genes in IECs, Pggt1bfl/fl or Rhoafl/fl mice were cross-
bred with villin-Cre or villin-Cre-ERT2 mice (22). Pggt-IβTiΔIEC mice were 
crossbred with Casp8fl/fl or Rip3k–/– in order to impair apoptosis or necrop-
tosis, respectively. Ethanolic tamoxifen (Sigma-Aldrich) solution was 
emulsified in sunflower oil and administered for 3 consecutive days by 
i.p. or intrarectal routes (1 mg/mouse/day). Littermates carrying loxp- 
flanked target genes but not the Cre-recombinase were used as control. 
Genotyping was performed by PCR in ear or tail genomic DNA. Animal 
studies were conducted in a sex- and age-matched manner using litter-
mates for each experiment. Both male and female animals were used 
at the age of 6–10 weeks. All mice were kept under specific pathogen–
free conditions. Except for DSS-induced colitis, animals from different 
experimental groups were cohoused in every experiment. Mice were 
routinely screened for pathogens according to Federation for Labora-
tory Animal Science Associations (FELASA) guidelines.
DSS-induced colitis. Colitis was induced in C57BL/6J mice by 
daily supplementation of drinking water with 2% w/v dextran sulfate 
sodium (MP Biomedicals) for 7 days (47, 48); DSS was withdrawn on 
day 7, when animals received normal drinking water. Animals were 
sacrificed 10 days after starting of the DSS treatment.
Mouse endoscopy. Gut status of mice was monitored by high-reso-
lution mouse video endoscopy as previously described (49). Mice were 
anesthetized with 2%–2.5% isoflurane in oxygen during endoscopy. Any 
colitis was scored basing on the following 5 parameters: thickening of the 
colon wall, changes in the normal vascular pattern, presence of fibrin, 
mucosal granularity, and stool consistency. Endoscopic scoring of each 
parameter was performed (0 to 3), leading to a cumulative score between 
0 (no signs of inflammation) and 15 (very severe inflammation) (50).
tion of the Rho-associated kinase (ROCK), as well as deletion of 
the Rho-A target MLC kinase (MLCK), has been shown to result in 
incomplete cell extrusion (27). Microscopically, ROCK and MLCK 
inhibition resulted in a predominant appearance of funnel-like 
structures (arrested shedding events) built up by reorganized actin 
filaments and tight junction proteins along lateral membranes of 
shedding cells. However, the final consequence of the accumula-
tion of arrested shedding events has not been considered previously 
(27). Such accumulation of epithelial funnel-like structures could 
also be observed in the intestine of Pggt-IβTiΔIEC mice, indicating 
that redistribution of tight junction proteins takes place, but com-
plete extrusion and resolution of shedding does not occur. Altered 
cell shedding in the absence of appropriate Rho-A function finally 
resulted in epithelial instability and loss of barrier function, leading 
to chronic intestinal inflammation. Hence, our observations con-
firmed that blockade of cell shedding due to cytoskeleton altera-
tions, mediated by Rho-A among others, is an essential mechanism 
for disturbances of epithelial integrity.
The newly gained insights into Rho-A–dependent IEC intrin-
sic mechanisms involved in the initiation of intestinal barrier 
dysfunction open new avenues for potential interventional or 
translational approaches. Therapeutically triggered induction of 
Rho-A signaling via specific Rho activators or induction of Rho 
downstream signaling molecules such as ROCK might therefore 
represent a novel strategy for maintenance of intestinal integrity 
and prevention or healing of mucosal damage in IBDs and other 
inflammatory disorders of the intestine.
Methods
Animal models. Mice carrying LoxP-flanked Pggt1b (Pggt1bfl/fl) (26), cas-
pase 8 (Casp8fl/fl) (4), Rhoa alleles (Rhoafl/fl) (21), as well as Rip3k KO mice 
(46), were described previously. Pggt1bfl/fl mice were provided by Martin 
Figure 13. Rho-A dysfunction in Pggt-IβTiΔIEC mice. (A) Western blot of Rho-A in membrane-bound and cytosolic proteins from IECs of Pggt-IβTiΔIEC and 
control mice; blots are representative of 3 experiments. (B) Representative Rho-A immunostaining (red) in colon from Pggt-IβTiΔIEC mice (2 independent 
experiments). Nuclei were counterstained with Hoechst. Original magnification, ×63. (C) GTP-bound Rho-A in IECs from control and Pggt-IβTiΔIEC mice. 
Mean values ± SEM; n = 5 samples/group; †P ≤ 0.05 vs. control; independent samples t test. (D) Western blot of phosphorylated MLC-2 and Np-Rap1A in 
IECs from control and Pggt-IβTiΔIEC mice; blots are representative of 2 experiments.
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oral gavage (4,000 g/mol average molecular weight of FITC-Dextran). 
Serum was collected 4 hours after gavage, and FITC concentration was 
determined spectrophotometrically using FITC-Dextran as standard.
In vivo cell shedding. In short (5, 27), mice were anesthetized by 
ketamin/xylazin i.p. injection, and the intestine was exteriorized and 
opened. The mucosa was topically stained with acriflavine (Sigma- 
Aldrich) and rhodamine-dextran (10,000 g/mol) as luminal dye 
(Invitrogen). Surgical preparation was pinned up on a coverslide and 
mounted in a chamber for perfusion of saline solution. Time-sequen-
tial Z-stacks images of the villus tip were taken with a confocal micro-
scope (Leica Microsystems).
Quantification of epithelial cell shedding. Epithelial cell shedding 
was quantified by several techniques. On one side, the cell shedding 
rate was quantified by the counting of cell shedding events detected by 
Human samples. Human material was obtained from Depart-
ment of Medicine I, University Clinic Erlangen, Erlangen, Germany; 
and Department of Gastroenterology, Humanitas Research Hospital, 
Milan, Italy. The collection of samples was approved by the local eth-
ical committee and the institutional review board of the University of 
Erlangen-Nuremberg and Humanitas Research Hospital, and each 
patient gave written informed consent. Tissue samples were embed-
ded in a convenient matrix for cryosectioning and frozen at –80°C 
or freshly used for IEC isolation. Clinical information of patients 
included in our studies is summarized in Supplemental Tables 1–4.
Intestinal epithelial permeability assessment (FITC-Dextran). Intes-
tinal permeability was assessed in vivo (51). In brief, Pggt-IβTiΔIEC and 
control mice were deprived of food and water for 4 hours. Afterward, 
60 mg FITC-Dextran (Sigma-Aldrich)/100 g body weight was given by 
Figure 14. Treatment of Pggt-IβTiΔIEC mice with the Rho activator CN03. Three independent experiments. (A) Representative colonic endoscopy pictures. 
(B) Endoscopy score. (C) Histologic analysis: representative pictures from H&E staining. Original magnification, ×20. (D) Damage score quantification. (E) 
Il1b and Il6 expression in duodenum measured by qPCR. Mean values ± SEM from 3 independent experiments; (control, n = 4; Pggt-IβTiΔIEC, n = 6; CN03,  
n = 6 per group) in B, D, and E. †P ≤ 0.05 vs. control mice; *P ≤ 0.05 vs. Pggt-IβTiΔIEC mice; 1-way ANOVA with LSD multiple comparisons test in B, D, and E.
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BioLegend); CD8α, 1:200 (catalog 14-0081, eBioscience); Ki67, 
1:1,000 (catalog ab16667, Abcam); Myosin-IIA, 1:200 (catalog 3403, 
Cell Signaling Technology); cleaved caspase-3, 1:750 (catalog AF835, 
R&D Systems); and Rho-A, 1:100 (catalogs sc-418 and sc-179, Santa 
Cruz Biotechnology Inc.). Biotinylated-Streptavidin antibody pairs 
were used for detection (1:100–1:200, 30 minutes at room tempera-
ture (RT), Santa Cruz Biotechnology Inc., BioLegend). In some cases, 
direct dye–labeled secondary antibodies were used (1:100, 30 minutes 
at RT, BioLegend). Actin fiber staining was performed using phalloidin 
(Invitrogen). In situ cell death detection kit (Roche Diagnostics) was 
used for detection of TUNEL+ cells. For electron microscopy, glutaral-
dehyde-fixed material was used. After embedding in Epon Araldite, 
ultrathin sections were cut and analyzed using a Zeiss EM 906.
Quantification of IHC. We have exclusively measured the aver-
age intensity of GGTase-Iβ or Rap1A signal from epithelium. Using 
ImageJ software, EpCAM+ cells (IECs) were selected, the mean inten-
sity of epithelial GGTase-Iβ or Rap1A signal was detected, and the 
overall number of IECs was counted based on nuclear staining. The 
overall number of IECs per image was used for normalization. Using 
this strategy, we analyzed 2 representative images per experiment in 
n = 4 experiments. Overall, 8 images from each group (control and 
inflamed) were included into data interpretation.
The number of CD4+, F4/80+, MPO+, and CD8+ cells per field was 
counted using ImageJ software. A total of 3 different images/sample 
(×20 objective) were counted, and the average cell number was calcu-
lated accordingly.
RNA isolation and quantitative PCR (qPCR) analysis. Total RNA 
was isolated from tissues or IECs using RNeasy Mini kit (QIAGEN). 
Synthesis of cDNA was performed using reverse transcriptase. Gene 
expression was measured by real-time PCR (Bio-Rad) with SYBR 
Green and QuantiTect primers (QIAGEN). Gene expression was nor-
malized to the housekeeping gene HPRT expression.
Gene expression assay (mouse; array data accessible through through 
NCBI’s GEO [GSE72781]). Gene-chip experiments were performed by 
the Erlangen University core facility (n = 3 per group). RNA quality 
was first assessed by Eukaryotic Total RNA Nano (Agilent Technolo-
gies), and gene expression was measured using the Affymetrix mouse 
430 2.0 chip. For multiple gene array testing, including differential 
expression analysis, the software package FlexArray (Michal Blaze-
jczyk, Mathieu Miron, and Robert Nadon [2007], Genome Quebec, 
Montreal, Canada; http://www.gqinnovationcenter.com/services/
bioinformatics/index.aspx?l=e) was used. GO-based analyses were 
performed using the online tool Database for Annotation, Visualiza-
tion, and Integrated Discovery (DAVID) and the platform Ingenuity.
Gene expression assay (human; array data accessible through through 
NCBI’s GEO [GSE72780]). More than 30 samples were collected from 
the gut of patients suffering from CD or control patients. IECs were iso-
lated from patient specimen as described. RNA was isolated using the 
RNeasy Lipid Tissue Mini kit according to manufacturer’s instructions 
(QIAGEN). Nine samples were chosen for GeneChip analysis accord-
ing to the following inclusion criteria: histopathological confirmation 
of inflammation status, acceptable RNA quality as confirmed by a 
bioanalyzer, and comparable expression of the epithelial marker villin.
GeneChip analysis. Genome-wide expression analysis was per-
formed in the Genomics core facility of the Institute of Human 
Genetics of the University Erlangen-Nuremberg using the Affymetrix 
GeneChip Human Genome U133 Plis 2.0 Arrays. For multiple gene 
in vivo cell imaging. The number of cell shedding events was normal-
ized by the length of the basal membrane on the individual pictures 
and the time of image acquisition. A total number of 10 animals were 
analyzed. On the other hand, we have also counted the number of 
leakage and “permeable cells” (our terminology for cells with dextran 
in the cytoplasm) in 2 single in vivo images from each specimen (n = 8 
animals). Finally, a similar method was performed in order to quantify 
the number of arrested versus completed cell shedding events. How-
ever, in this case, we took advantage of actin staining with phalloidin, 
which allowed us to detect the cytoskeleton protein redistribution 
occurring in early stages of the cell shedding process. We thus quan-
tified the overall cell shedding rate, the distribution of different stages 
of cell shedding, and the appearance of dextran-permeable cells.
IEC isolation. Murine gut tissues and human surgical specimens 
were freshly used for IEC isolation. Therefore, tissue was incubated 
in a solution containing DTT and EDTA (34). Purification of IECs was 
performed by Percoll gradient.
Crypt isolation and organoid culture. Small intestine was asepti-
cally isolated, washed, and cut. Intestinal fragments were washed, 
incubated in chelation buffer (containing EDTA), and vigorously 
resuspended in order to isolate intestinal crypts. Crypts were embed-
ded in Matrigel (BD Biosciences) on ice and seeded in surface cell cul-
ture plates. After polymerization of Matrigel, basal culture medium 
was added to the culture (24). The entire medium was changed every 
2 days, and organoids were passaged weekly. Organoids were treated 
in vitro with 0.5 μg/ml tamoxifen; the caspase inhibitor Z-VAD (10 
μg/ml) (Bachem) or Necrostatin-1 (30 μM) (Sigma-Aldrich), and 
cytokines (20 ng/ml).
Quantification of cell viability and death in crypt organoid cultures. 
We used a cell viability imaging kit (Roche Diagnostics) in order to 
quantify the death/destruction of organoids after in vitro treatment 
of organoids with tamoxifen and subsequent deletion of Pggt1b gene. 
This kit includes 3 different dyes in order to identify nuclei (blue dye), 
viable cells (green dye), and dead cells (red dye). Identification of 
dead cells is based on permeability of those cells due to destruction 
of the cell membrane. Detection of cell viability is based on metabolic 
activity, which allows the cleavage of the substrate, resulting in green 
fluorescence. Nuclear staining (blue) enabled normalization of results 
based on the overall number of detected cells. Quantification of the 
mean intensity of dead cell signal (red signal) and nuclear signal (blue 
signal) was performed using ImageJ software.
Histology, IHC, and electron microscopy. Formalin-fixed paraf-
fin-embedded samples were used for H&E staining and histopatho-
logical analysis. The score of the histological damage in colon, ileum, 
and duodenum took into account the 2 parameters epithelial erosion 
and distorted tissue architecture. Each parameter was scored (none, 
0; mild, 1; pronounced, 2; severe, 3), and both results were summed 
afterward (maximum score of 6). Scoring was performed in a blinded 
fashion. IHC was performed in cryosections, using TSA Cy3 (Perkin-
Elmer). Images were acquired by fluorescence microscopy (Olympus 
or Leica) or by confocal microscopy (Leica TCS SP5 or Leica TCS 
SP8). The following primary antibodies were used overnight at 4°C: 
GGTase-Iβ, 1:100 (catalog sc-18996, Santa Cruz Biotechnology Inc.); 
Np-Rap1A, 1:100 (catalog sc-1482, Santa Cruz Biotechnology Inc.; for 
exclusive detection of Np-Rap1A); EpCAM, 1:100 (catalogs 324201 
and 118207, BioLegend); MPO, 1:250 (catalog ab9535, Abcam); CD4, 
1:200 (catalog 100506, BioLegend); F4/80, 1:100 (catalog 123101, 
Downloaded from http://www.jci.org on February 18, 2016.   http://dx.doi.org/10.1172/JCI80997
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
6 2 5jci.org   Volume 126   Number 2   February 2016
Rho-A activation assay. Rho-A activation status was measured by 
using Rho-A G-LISA Activation Assay (catalog BK214, Cytoskeleton 
Inc.), following manufacturer’s instructions.
Rho activator treatment. Mice were randomly distributed into 2 
groups (Pggt-IβTiΔIEC ± CN03) and Pggt-Iβflx littermates were used as 
controls. Mice were treated with the Rho Activyator II (catalog CN03, 
Cytoskeleton Inc.) before onset of intestinal disease (oral, 0.3 μg/mouse; 
intrarectal, 0.5 μg/mouse). Tamoxifen was administered intrarectally. 
Animals were sacrificed 10 days after starting tamoxifen induction.
Statistics. Significance analysis of normally distributed data was 
performed using 2-tailed Student’s t test. Error bars represent ± SEM. 
For multiple comparisons, data were analyzed by 1-way ANOVA and 
LSD post-hoc test (IBM SPSS Statistic 21). P values of less than 0.05 
and 0.001 were considered significant and highly significant.
Study approval. Animal protocols were approved by the Institu-
tional Animal Care and Use Committee of the University of Erlangen. 
Animal studies were performed in accordance with German law and 
with approval from Regierung Mittelfranken (Ansbach, Germany). 
Collection of human samples was approved by Ethics Committee of 
the Department of Medicine of the Univeristy of Erlangen-Nuremberg 
(Erlangen, Germany) and Humanitas Research Hospital. Each patient 
gave written informed consent.
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array evaluations, including advanced significance analysis, cluster-
ing, and gene ontology-based gene class testings, ANOVA of the soft-
ware package Partek Genomics Suite were used. In brief, GC-RMA 
algorithm was applied to CEL-files of all microarrays. Next, log scale 
transformation, grouping, and baseline definition were performed. 
For advanced significance analysis, the following parameters were 
applied: unpaired t test, P < 0.05, fold-change > 1.5, K-Means Clus-
tering. Redundancies in gene list (e.g., cluster probe test lists) were 
eliminated, and gene ontology enrichment analysis was performed, 
allowing the detection of statistically overrepresented protein func-
tions (GO terms) in a subset of genes. More than 54,000 expression 
tags were analyzed, from which 129 significantly (P < 0.05) differed 
(fold-change > 1.5) between IECs from inflamed and uninflamed gut 
areas of CD patients.
Immunoblotting. Protein extracts were obtained by suspension 
and incubation in mammalian protein extraction reagent (Thermo 
Scientific) supplemented with protease and phosphatase inhibitor 
tablets (Roche Diagnostics). For membrane/cytosol fraction separa-
tion, lysis buffer (RIPA) with and without detergents and high-speed 
centrifugation steps were used. Protein extract was cleared by cen-
trifugation, protein concentration was measured by Bradford assays, 
and denaturation was performed by boiling in LDS sample buffer 
(Thermo Scientific). Afterward, proteins were separated by SDS-
PAGE gels, blotted onto nitrocellulose or polyvinylidene fluoride 
(PVDF) membranes, and blocked with 5% nonfat milk. Membranes 
were incubated overnight at 4°C with the following primary antibod-
ies: GGTase-Iβ, 1:2,500 (catalog WH0005229M2, Sigma-Aldrich); 
Np-Rap1A, 1:1,000 (catalog sc-1482, Santa Cruz Biotechnology Inc.); 
Rho-A, 1:500 (catalog sc-179, Santa Cruz Biotechnology Inc.); phos-
pho-MLC2, 1:1,000 (catalog 3671, Cell Signaling Technology); Cdc42, 
1:1,000 (catalog 2466, Cell Signaling Technology); Rac-1, 1:1,000 
(catalog sc-95, Santa Cruz Biotechnology Inc.); Rho-B, 1:1,000 (cata-
log 2098, Cell Signaling Technology); Rho-C, 1:1,000 (catalog 3430, 
Cell Signaling Technology); and AHRR, 1:1,000 (catalog sc-138745, 
Santa Cruz Biotechnology Inc.). Convenient HRP-linked secondary 
antibodies were used (incubation for 90 minutes at RT), and chemo-
luminescence was detected by using ECL Western blotting substrate 
(Thermo Scientific). Protein expression was compared with the level 
of actin, 1:2,000 (catalog 4967, Cell Signaling Technology). Inclusion 
of a positive control sample (protein lysate from testis) allowed reliable 
identification of the 38–43 kDa protein GGTase-I.
Proteomic assay. Of the total protein from purified IECs, 20 μg 
were digested using a modified filter aided sample preparation (FASP) 
method (52). Three biological replicates were included, except where 
indicated. Reversed-phase nano-UPLC separation of tryptic peptides 
and mass spectrometric analysis using an ion-mobility enhanced 
data-independent analysis workflow were performed as previously 
described (52). All samples were analyzed in 3 technical replicates.
Cytoskeleton protein activation array. Activation of 64 cytoskele-
ton-related proteins was assessed by measuring their phosphorylation 
status using Cytoskeleton II Phospho Antibody Array (catalog PCP141, 
Cytoskeleton Inc.), following manufacturer’s instructions.
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